HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38

被引:42
|
作者
Xuan, Tong
Zhang, J. Allen
Ahmad, Imran
机构
[1] Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA
[2] Hospira Inc, Lake Forest, IL 60045 USA
[3] NeoPharma Inc, Waukegan, IL 60085 USA
关键词
HPLC; SN-38; liposomes; validation; entrapment efficiency;
D O I
10.1016/j.jpba.2005.10.051
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple HPLC method was developed for quantification of SN-38, 7-ethyl-10-hydroxycamptothecin, in a novel liposome-based formulation (LE-SN38). The chromatographic separation was achieved on an Agilent Zorbax SB-C18 (4.6 mm x 250 mm, 5 mu m) analytical column using a mobile phase consisting of a mixture of NaH2PO4 (pH 3.1, 25 mM) and acetonitrile (50:50, v/v). SN-38 was detected at UV wavelength of 265 nm and quantitatively determined using an external calibration method. The limit of detection (LOD) and limit of quantitation (LOQ) were found to be 0.05 and 0.25 mu g/mL, respectively. The individual spike recovery of SN-38 ranged from 100 to 101%. The percent of relative standard deviation (%R.S.D.) of intra-day and inter-day analyses were less than 1.6%. The method validation results confirmed that the method is specific, linear, accurate, precise, robust and sensitive for its intended use. The current method was successfully applied to the determination of SN-38 content and drug entrapment efficiency in liposome-based formulation, LE-SN38 during early stage formulation development. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:582 / 588
页数:7
相关论文
共 50 条
  • [41] Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats
    Kaneda, N
    Hosokawa, Y
    Yokokura, T
    Awazu, S
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1997, 20 (09) : 992 - 996
  • [42] Investigating the Impact of SN-38 on Mouse Brain Metabolism Based on Metabolomics
    Zhu, Xiaodong
    Huang, Ya
    Ding, Jia
    Liu, Jianguo
    Cui, Changmeng
    Han, Guangkui
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 2435 - 2447
  • [43] Development of ELISAs for irinotecan and its active metabolite SN-38
    Saita, T
    Fujito, H
    Mori, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (08) : 911 - 916
  • [44] SN-38 loaded polymeric micelles to enhance cancer therapy
    Gu, Quanrong
    Xing, James Z.
    Huang, Min
    He, Chuan
    Chen, Jie
    NANOTECHNOLOGY, 2012, 23 (20)
  • [45] Liposomalization of SN-38 as active metabolite of CPT-11
    Sadzuka, Y
    Takabe, H
    Sonobe, T
    JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) : 453 - 459
  • [46] DELIVERY AND ACTIVITY OF SN-38 BY SACITUZUMAB GOVITECAN IN CNS TUMORS
    Brenner, Andrew
    Floyd, John
    Pandey, Renu
    Chiou, Jennifer
    Surapreneni, Prathiba
    Kaklamani, Virginia
    Lathrop, Kate
    Crownover, Richard
    Caron, Jean Louis
    Tiziani, Stefano
    NEURO-ONCOLOGY, 2020, 22 : 42 - 42
  • [47] In vitro activation of irinotecan to SN-38 by human liver and intestine
    Ahmed, F
    Vyas, V
    Cornfield, A
    Goodin, S
    Ravikumar, TS
    Rubin, EH
    Gupta, E
    ANTICANCER RESEARCH, 1999, 19 (3A) : 2067 - 2071
  • [48] Interactions of oxaliplatin with the topoisomerase I inhibitors topotecan and SN-38
    Erlichman, C
    Boerner, S
    Kaufmann, SH
    ANNALS OF ONCOLOGY, 1998, 9 : 59 - 59
  • [49] Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours
    Brenner, A. J.
    Pandey, R.
    Chiou, J.
    Floyd, J.
    Garcia, M.
    Surapaneni, P.
    Kaklamani, V.
    Lathrop, K.
    Crownover, R.
    Caron, J. L.
    Tiziani, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S401 - S401
  • [50] The order of administration of trastuzumab to SN-38 infl uences SN-38's cytotoxicity in gastric cancer cell lines with or without HER2 expression
    Yamade, M.
    Sugimoto, M.
    Nishino, M.
    Uotani, T.
    Sahara, S.
    Furuta, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 46 - 47